Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865766 | 1.00 | CHRM1 (0.38) | CHRM1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL20153492 | 1.00 | CHRM1 (0.38) | CHRM1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL17865726 | 0.90 | HRH3 (0.35) | KDM4EMMP2ADAM17ADAMTS5ALDH1A1 | |
| SCHEMBL20153498 | 0.90 | HRH3 (0.35) | KDM4EMMP2ADAM17ADAMTS5ALDH1A1 | |
| SCHEMBL17969616 | 0.90 | HRH3 (0.35) | KDM4EMMP2ADAM17ADAMTS5ALDH1A1 | |
| SCHEMBL20153499 | 0.86 | MMP2 (0.32) | MMP2ADAM17ADAMTS5 | |
| SCHEMBL17999632 | 0.85 | PIK3CD (0.35) | MEN1MAPTKMT2AMMP2ADAM17 | |
| SCHEMBL17865774 | 0.85 | NPC1 (0.39) | CHRM1MMP2ADAM17ADAMTS5 | |
| SCHEMBL17865773 | 0.85 | NPC1 (0.39) | CHRM1MMP2ADAM17ADAMTS5 | |
| SCHEMBL20952055 | 0.85 | ALDH1A1 (0.35) | KDM4EMEN1KMT2AMMP2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | claimed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | claimed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | claimed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | claimed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | claimed |
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | ADH1A, ADH1C, SLC10A1 | CHRM1 295/4885KDM4E 1875/4885MEN1 1739/4885 |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | SLC1A2, SLC7A11, SLC18A2 | CHRM1 1215/4885KDM4E 1914/4885MEN1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.